As hope of a quick end to the COVID-19 pandemic fades, both policymakers and analysts are shifting focus to restarting the economy. As of late April, more than 26 million Americans had filed for unemployment. Estimates of the cost of every month of partial shutdown are as high as $1.07 trillion...

Vaccines play a crucial role in improving global public health, with the ability to stem the spread of infectious diseases and the potential to eradicate them completely. Compared with pharmaceuticals that treat disease, however, preventative vaccines for infectious diseases have received far...

The United States has recently — and belatedly — come to recognize opioid addiction as a public health crisis. What has gone mostly unrecognized is the degree to which this crisis is intertwined with U.S. intellectual property law and related elements of U.S. innovation policy. Innovation...

Fair competition law and public health law talk past each other when discussing pharmaceutical pricing and distribution. The former cannot agree on the relevant definition of consumer welfare. The latter does not fully comprehend the highly complex but inherently collective nature of...

Workplace drug testing is routinely criticized as irrational, unproductive, and even motivated by nefarious intent. This article analyzes the costs and benefits of workplace drug testing within the context of a complex business environment. Even in a drug-policy vacuum, workplace drug testing is...

This article critically examines the successes and failures of the current internal and external regulatory regimes for ensuring the delivery of patient safety in public hospitals. It argues that governments should develop a holistic approach to regulation through the enhancement of existing...

In 2019, U.S. pharmaceutical companies paid $3.6 billion to physicians in the form of gifts to promote their drugs. The practice of offering financial incentives has raised concerns about potential conflict of interest. To curb such inappropriate financial relationships between healthcare...

Regulators can avert corporate behaviour that inflicts risks on society, but is nevertheless compliant with the law. Such regulatory interventions beyond the law evoke contentious questions about their objects, legitimacy, methods, and the norms employed. No framework yet exists to analyse these...

This study explores the potential impact of the Australian Plain Packaging Act 2011 (APPA) on public health by analyzing its functional and legal properties.Ch. 1 is devoted to the analysis of functional properties of APPA. By preventing socially beneficial functions of trademarks, APPA is bound...